Figure 1. Intravenous leiomyomatosis. (a) Photograph obtained from a histopathological study of a tissue section shows leiomyoma with abundant blood vessels in dilated veins. (b) An enlarged image of the dotted rectangle area shown in (a).
| Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |
| Journal website https://www.jocmr.org |
Letter to the Editor
Volume 14, Number 3, March 2022, pages 142-145
Potential Biomarkers Associated With the Nature of Uterine Benign Mesenchymal Tumors
Figure
Table
| Mesenchymal tumor types | Age, years | N | Protein expressiona | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SMA | CAV1 | CCNB | CCNE | LMP2 | NT5DC2 | CD133 | Ki-67 | |||
| aStaining score of expression of smooth muscle actin (SMA), caveolin 1 (CAV1), cyclin B (CCNB), cyclin E (CCNE), low molecular protein 2 (LMP2), 5’-nucleotidase domain containing 2 (NT5DC2) and Ki-67 from results of immunohistochemistry (IHC) experiments. aProtein expression: estimated protein expressions by immunoblot analysis, IHC and/or quantitative-polymerase chain reaction (RT-PCR). -/+: partially positive (5-10% of cells stained); Focal+: focal-positive (focal or sporadic staining with less than 5% of cells stained); ++: staining with 5% or more, less than 90% of cells stained; +++: diffuse-positive (homogeneous distribution with more than 90% of cells stained); -: negative (no stained cells). U.LANT-like tumor: uterine leiomyomatoid angiomatous neuroendocrine tumor-like tumor: LMP2 [10-12]; CCNE [10, 12]; CAV1 [13]; NT5DC2 [14]; CD133 [9]; Ki-67 [11, 12]. STUMP: smooth muscle tumor of uncertain malignant potential [15, 16]. CCNE, LMP2, and CAV1 are potential biomarkers for human uterine mesenchymal tumors. bLANT: leiomyomatoid angiomatous neuroendocrin tumor (LANT) is described as a dimorphic neurosecretory tumor with a leiomyomatous vascular component [17]. NA: no answer. | ||||||||||
| Normal | 30s - 80s | 74 | +++ | - | - | - | +++ | - | - | - |
| Leiomyoma (LMA) | 30s - 80s | 40 | +++ | ++ | -/+ | -/+ | +++ | -/+ | - | +/- |
| Ordinally leiomyoma | 30 | +++ | ++ | -/+ | - | +++ | -/+ | +/- | ||
| Cellular leiomyoma | 10 | ++ | ++ | -/+ | -/+ | ++ | -/+ | +/- | ||
| STUMP | 40s - 60s | 12 | ++ | ++ | + | -/+ | -/+ | -/+ | NA | +/+++ |
| Bizarre leiomyoma | 40s - 50s | 4 | ++ | ++ | -/+ | + | Focal+ | + | NA | + |
| Intravenous LMA | 50s | 3 | ++ | ++ | + | + | - | NA | ++ | + |
| Benign metastasizing | 50s | 1 | ++ | ++ | + | ++ | - | NA | NA | ++ |
| Leiomyosarcoma | 30s - 80s | 54 | -/+ | + | ++ | +++ | -/+ | ++ | ++ | ++/+++ |
| U.LANTb-like tumor | 40s | 1 | ++ | + | NA | ++ | - | NA | NA | - |